[DOI] [PMC free article] [PubMed] [Google Scholar] 169.Rajman L., Chwalek K., Sinclair D.A
The Aib substitution prevents enzymatic destruction
The FDA recently approved versions of GLP-1 medication - including Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide) - for chronic weight management
Some medications and supplements are offered without adequate warnings about their limitations
In consideration of the multiple metabolic and cardiovascular effects seen in subjects treated with GLP-1RAs and SGLT-2is (e.g., reduction of hyperglycemia, weight loss, free/fat mass and bone remodeling, anti-atherosclerosis, natriuresis), it is reasonable to speculate that GH and IGF-1 may play a about a relevant role in this context